young man 30 year old, with type 1 diabetes. Is professional athlete and has

Regarding the safe resumption of creatine supplementation in a 30-year-old professional athlete with type 1 diabetes, who experienced an increase in plasma creatinine and low estimated glomerular filtration rate (eGFR) that normalized after two weeks off creatine:

• The transient rise in serum creatinine observed during creatine supplementation is commonly due to the increased conversion of supplemented creatine into creatinine, which does not necessarily indicate true renal impairment NICE NG203 Młynarska et al. 2025.
• Creatine supplementation, especially creatine monohydrate taken at recommended doses (3–5 g/day after loading), is generally safe and well-tolerated in healthy individuals and clinical populations, including those with diabetes, without causing clinically meaningful nephrotoxicity or hepatotoxicity NICE NG203 Młynarska et al. 2025.
• In individuals with increased muscle mass and physical activity - such as professional athletes - baseline creatinine levels may be elevated due to higher muscle turnover; creatine supplementation further increases plasma creatinine via its metabolic conversion, potentially lowering eGFR estimates that rely on serum creatinine measurement, without reflecting actual decreased kidney function NICE NG203 Młynarska et al. 2025.
• Normalisation of serum creatinine after cessation of creatine suggests that the prior elevation was a benign effect of supplementation rather than true renal injury NICE NG203 Młynarska et al. 2025.
• However, given that this patient has type 1 diabetes—a population at risk for diabetic nephropathy—a prudent approach would involve careful clinical and biochemical renal monitoring if creatine supplementation is resumed, ideally including markers less influenced by muscle mass or creatine metabolism such as cystatin C-based eGFR NICE NG203 Schunk & Zimmermann 2025.
• Combined creatine supplementation with regular exercise has demonstrated beneficial effects on muscle mass, insulin sensitivity, and glycemic control, which may be advantageous in diabetes management when carefully monitored NICE NG203 Młynarska et al. 2025.
• Creatine's safety profile in individuals with diabetes has been supported, with randomized controlled trials showing no deterioration of renal function under creatine supplementation at standard dosages, but data on type 1 diabetes are limited and require individualized assessment NICE NG203 Młynarska et al. 2025.

In summary, the patient may safely resume creatine supplementation if it is with recommended dosing and under clinical supervision, including monitoring kidney function with consideration of creatinine-independent measures, given his type 1 diabetes and prior transient creatinine elevation likely due to supplementation rather than actual renal impairment.